MedTrace Logo

IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.

NCT01967407 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-11-19

No results posted yet for this study

Summary

The aim of the study is the evaluation of the ablation efficiency of the percutaneous irreversible electroporation (IRE) as primary ablation therapy of locally confined renal cell carcinoma (≤4cm, see inclusion and exclusion criteria).

The ablation success will be proofed by magnet resonance imaging (MRI) and histologically after partial kidney resection or nephrectomy 4 weeks after IRE. Hypotheses: Kidney tumors ≤4cm can be ablated completely by percutaneous IRE. Surrounded structures and renal tissue can be preserved.

Conditions

  • Kidney Tumor
  • Renal Cell Cancer

Interventions

PROCEDURE

Irreversible Electroporation (IRE)

Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.

Sponsors & Collaborators

  • University of Magdeburg

    lead OTHER

Principal Investigators

  • Uwe- B. Liehr, Dr. med. · Department of Urology, University Magdeburg, Germany.

  • Martin Schostak, Prof. Dr. · Department of Urology, University Magdeburg, Germany

  • Johann J. Wendler, Dr. med. · Department of Urology, University Magdeburg, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-12-31
Completion
2016-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01967407 on ClinicalTrials.gov